Exosomes from Adipose Tissues Derived Mesenchymal Stem Cells Overexpressing MicroRNA-146a Alleviate Diabetic Osteoporosis in Rats

Zhang, Lei; Wang, Qinghai; Cheng, Jiaxiang

doi:10.1007/s12195-021-00699-4

Cited by 19 publications

(19 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ADMSCs secrete phenotypically characterized miR-146a-containing exosomes, due to the over-expression of miR-146a in diabetic osteoporosis. Exosomes containing miR-146a can reduce the production of inflammatory cytokines in high-glucose-treated osteoclasts and inhibit bone resorption, which had the most effective effect on bone loss in diabetic osteoporotic rats [ 89 ]. It has been shown that miR-5106 is highly enriched in macrophage 2-derived exosomes (M2D-Exos), and can be transferred to BMSCs, targeting SIK2 and SIK3 genes to promote osteoblast differentiation [ 44 ].…”

Section: Role Of Exosomes As Drug Delivery Systems In Bone-related Di...mentioning

confidence: 99%

Advances in the Study of Exosomes as Drug Delivery Systems for Bone-Related Diseases

Huang

Wang

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Bone-related diseases are major problems and heavy burdens faced by modern society. Current clinical approaches for the treatment of these pathological conditions often lead to complications and have limited therapeutic efficacy. In this context, the development of nanotherapeutic platforms, such as extracellular vesicles, can improve the relevant therapeutic effects. In particular, exosomes are nano-sized, lipid bilayer extracellular vesicles secreted by many cells in mammals. Due to their innate capacity to transport materials—including proteins, lipids, and genes—among cells, as well as their innate attraction to target cells, they are considered to be a crucial medium for cell communication and are involved in a number of biological processes. Exosomes have been used as drug delivery vehicles in recent bone tissue engineering studies, in order to regulate bone homeostasis. However, the precise workings of the exosome regulatory network in maintaining bone homeostasis and its potential for treating bone injury remain unclear. To provide a fresh perspective for the study of exosomes in drug delivery and bone-related diseases, in this paper, we review recent studies on the roles of exosomes for drug delivery in bone homeostasis and bone-related diseases, as well as the composition and characteristics of exosomes and their regulatory roles in bone homeostasis and bone-related diseases, aiming to provide new ideas for the therapeutic application of exosomes in the treatment of bone-related diseases.

show abstract

Section: Role Of Exosomes As Drug Delivery Systems In Bone-related Di...mentioning

confidence: 99%

Advances in the Study of Exosomes as Drug Delivery Systems for Bone-Related Diseases

Huang

Wang

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Interestingly, Zhang et al (2021) revealed that AT-MSCs-derived exosomes could lower diabetic osteoporosis by interfering with the NLRP3 inflammasome activation in osteoclasts, thereby inhibiting the IL-1β and IL-18 secretion [ 171 ]. In streptozotocin-induced diabetic osteoporosis rats, administration of miR-146a-enriched exosomes inhibited the TNF-α, IL-18, and IL-1β expression, reduced inflammasome activation, and ultimately attenuated bone resorption and improved bone mass [ 172 ]. The miR-146a also inhibits osteoclast transformation by negative regulation of the critical regulators of NF-κβ signaling, thus suggesting that miR-146a can be a therapeutic target for treating inflammation-associated bone loss [ 173 ].…”

Section: Mscs-exosomes In Bone-associated Musculoskeletal Diseasesmentioning

confidence: 99%

Emerging role of mesenchymal stem/stromal cells (MSCs) and MSCs-derived exosomes in bone- and joint-associated musculoskeletal disorders: a new frontier

et al. 2023

View full text Add to dashboard Cite

Exosomes are membranous vesicles with a 30 to 150 nm diameter secreted by mesenchymal stem/stromal cells (MSCs) and other cells, such as immune cells and cancer cells. Exosomes convey proteins, bioactive lipids, and genetic components to recipient cells, such as microRNAs (miRNAs). Consequently, they have been implicated in regulating intercellular communication mediators under physiological and pathological circumstances. Exosomes therapy as a cell-free approach bypasses many concerns regarding the therapeutic application of stem/stromal cells, including undesirable proliferation, heterogeneity, and immunogenic effects. Indeed, exosomes have become a promising strategy to treat human diseases, particularly bone- and joint-associated musculoskeletal disorders, because of their characteristics, such as potentiated stability in circulation, biocompatibility, low immunogenicity, and toxicity. In this light, a diversity of studies have indicated that inhibiting inflammation, inducing angiogenesis, provoking osteoblast and chondrocyte proliferation and migration, and negative regulation of matrix-degrading enzymes result in bone and cartilage recovery upon administration of MSCs-derived exosomes. Notwithstanding, insufficient quantity of isolated exosomes, lack of reliable potency test, and exosomes heterogeneity hurdle their application in clinics. Herein, we will deliver an outline respecting the advantages of MSCs-derived exosomes-based therapy in common bone- and joint-associated musculoskeletal disorders. Moreover, we will have a glimpse the underlying mechanism behind the MSCs-elicited therapeutic merits in these conditions.

show abstract

“…ADSC-Exos can reduce bone resorption and recover bone loss by suppressing NLRP3 inflammasome activation in osteoclasts [ 80 ] and by antagonizing osteocyte-mediated osteoclastogenesis [ 81 ]. ADSC-Exos combined with microRNA-146a (miR-146a-Exo) were reported to restrain bone resorption by inhibiting pro-inflammatory cytokine production in high glucose-treated osteoclasts [ 82 ]. Exos derived from osteoblasts can inhibit osteoclast differentiation via the miR-503-3p/Hpse axis [ 83 ].…”

Section: Possible Mechanism Of Exos On Host Cells During Periodontitismentioning

confidence: 99%

Advances of exosomes in periodontitis treatment

et al. 2022

View full text Add to dashboard Cite

Periodontitis is an inflammatory disease initiated by dysbiosis of the local microbial community. Periodontitis can result in destruction of tooth-supporting tissue; however, overactivation of the host immune response is the main reason for alveolar bone loss. Periodontal tissue cells, immune cells, and even further activated osteoclasts and neutrophils play pro-inflammatory or anti-inflammatory roles. Traditional therapies for periodontitis are effective in reducing the microbial quantities and improving the clinical symptoms of periodontitis. However, these methods are non-selective, and it is still challenging to achieve an ideal treatment effect in clinics using the currently available treatments and approaches. Exosomes have shown promising potential in various preclinical and clinical studies, including in the diagnosis and treatment of periodontitis. Exos can be secreted by almost all types of cells, containing specific substances of cells: RNA, free fatty acids, proteins, surface receptors and cytokines. Exos act as local and systemic intercellular communication medium, play significant roles in various biological functions, and regulate physiological and pathological processes in numerous diseases. Exos-based periodontitis diagnosis and treatment strategies have been reported to obtain the potential to overcome the drawbacks of traditional therapies. This review focuses on the accumulating evidence from the last 5 years, indicating the therapeutic potential of the Exos in preclinical and clinical studies of periodontitis. Recent advances on Exos-based periodontitis diagnosis and treatment strategies, existing challenges, and prospect are summarized as guidance to improve the effectiveness of Exos on periodontitis in clinics.

show abstract

Exosomes from Adipose Tissues Derived Mesenchymal Stem Cells Overexpressing MicroRNA-146a Alleviate Diabetic Osteoporosis in Rats

Cited by 19 publications

References 36 publications

Advances in the Study of Exosomes as Drug Delivery Systems for Bone-Related Diseases

Advances in the Study of Exosomes as Drug Delivery Systems for Bone-Related Diseases

Emerging role of mesenchymal stem/stromal cells (MSCs) and MSCs-derived exosomes in bone- and joint-associated musculoskeletal disorders: a new frontier

Advances of exosomes in periodontitis treatment

Contact Info

Product

Resources

About